Results 161 to 170 of about 2,852,414 (315)

Evaluating uncertainties in an integrated approach for chemical risk assessment under REACH: more certain decisions?

, 2009
This thesis concentrates on uncertainty and variability in the risk assessment methodology for industrial chemicals as applied within the current regulatory framework for industrial chemicals in Europe, REACH (Registration, Evaluation, Authorisation and ...
Vermeire, T.G., Dep IRAS, Risk Assessment of Toxic and Immunomodulatory Agents   +2 more
core  

Loss of IGF‐1R impairs DNA‐PKcs recruitment to chromatin leading to defective end‐joining

Molecular Oncology, EarlyView.
IGF‐1R promotes radioresistance by facilitating DNA‐PKcs recruitment to chromatin, enabling non‐homologous end‐joining (NHEJ) repair of double‐strand breaks. Inhibition or loss of IGF‐1R disrupts this recruitment to damage sites, driving compensatory reliance on microhomology‐mediated end‐joining (MMEJ) repair.
Matthew O. Ellis, Jack V. Mills, Wojciech Niedzwiedz, Valentine M. Macaulay   +3 more
wiley   +1 more source

Improved risk analysis for large projects: Bayesian networks approach

, 2010
PhDGenerally risk is seen as an abstract concept which is difficult to measure. In this thesis, we consider quantification in the broader sense by measuring risk in the context of large projects.
Fineman, Milijana
core  

Technical assistance model and risk assessment summary

, 2020
Title from PDF caption (viewed on September 28, 2021).Covers OCLC #1269446281 and OCLC #1269446604.Serves as the Level 1 Modeling Protocol and Risk Assessment Summary for NW Metals Inc.This archived document is maintained by the State Library of Oregon ...

core  

Editorial: Trigger the microbiome changes in foods via metagenomic technologies: from diagnostic to potential changes in product safety or quality risk profiles. [PDF]

Front Bioeng Biotechnol
Tenea GN, Jarrin-V P, Lin L.
europepmc   +1 more source

USP29‐regulated noncanonical stabilization of the hypoxia‐inducible factor‐α in aggressive prostate cancer

Molecular Oncology, EarlyView.
We identify USP29 as the only DUB mirroring CA9 expression, a marker of hypoxia and HIF pathway activation associated with PCA aggressiveness. USP29 stabilizes HIF‐1α and HIF‐2α via a noncanonical mechanism that is independent of PHD/pVHL activity yet relies on proteasomal regulation, establishing USP29 as a previously unrecognized regulator of hypoxic
Amelie S Schober, Leire Moreno‐Cugnon, Laura Martínez‐Pérez, Amaia Ercilla, Amaia Zabala‐Letona, Adrián Vicente‐Barrueco, Maider Fagoaga‐Eugui, Saioa Garcia‐Longarte, Blanca Calle‐Ciborro, Encarnación Pérez‐Andrés, Onintza Carlevaris, Sara Pozo, Isabel Mendizabal, Ugo Mayor, Arkaitz Carracedo, Violaine Sée, Edurne Berra   +16 more
wiley   +1 more source

GPT-4 generated psychological reports in psychodynamic perspective: a pilot study on quality, risk of hallucination and client satisfaction. [PDF]

Front Psychiatry
Kim N, Lee J, Park SH, On Y, Lee J, Keum M, Oh S, Song Y, Lee J, Won GH, Shin JS, Lho SK, Hwang YJ, Kim TS.   +13 more
europepmc   +1 more source

Finding novel vulnerabilities of hypomorphic BRCA1 alleles

Molecular Oncology, EarlyView.
Synthetic lethality screens performed to identify novel vulnerabilities often model complete gene loss, thereby overlooking patient‐derived hypomorphic mutations. In this study, we have performed genome‐wide CRISPR screens on BRCA1 hypomorphic mutations, showing BRCA1I26A behaves like wild‐type, while BRCA1R1699Q mimics deficiency. Furthermore, we have
Anne Schreuder, Klaas de Lint, Hồ Mỹ Phúc Võ, Mariana M. Góis, Rosalie A. Kampen, Marta San Martin Alonso, Ilse Nootenboom, Veronica Garzero, Tiemen J. Wendel, Rob M. F. Wolthuis, Sylvie M. Noordermeer   +10 more
wiley   +1 more source

A novel water quality risk assessment framework for reservoir water bodies coupling key parameter selection and dynamic warning threshold determination. [PDF]

Sci Rep
Nong X, Zeng J, Chen L, Wei J, Zhang Y.
europepmc   +1 more source

Longitudinal genome‐wide aneuploidy measurements in circulating cell‐free DNA to predict lack of benefit from pembrolizumab in patients with metastatic urothelial cancer

Molecular Oncology, EarlyView.
Many patients with urothelial cancer do not benefit from treatment with pembrolizumab, while at risk of severe side effects. Changes in the levels of circulating tumor DNA early during treatment, measured by a simple and affordable assay that can be easily implemented in the clinic, can be used as a prognostic tool to identify these patients.
Youssra Salhi, Stavros Makrodimitris, Sandra van Wilpe, Iris te Paske, Vanja de Weerd, Corine M. Beaufort, Hans M. Westgeest, Jens Voortman, Maureen J. B. Aarts, Maud Rijnders, Astrid A. M. van der Veldt, Ronald de Wit, Niven Mehra, Saskia M. Wilting, Debbie G. J. Robbrecht   +14 more
wiley   +1 more source